Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 1,775 shares of the business’s stock in a transaction dated Friday, June 30th. The stock was sold at an average price of $10.94, for a total value of $19,418.50. Following the sale, the insider now owns 2,583,229 shares in the company, valued at approximately $28,260,525.26. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Thursday, July 13th, Hbm Healthcare Investments (Ca sold 57,175 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.53, for a total value of $602,052.75.
  • On Friday, July 7th, Hbm Healthcare Investments (Ca sold 2,695 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.52, for a total value of $28,351.40.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total value of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.96, for a total value of $93,795.68.
  • On Friday, April 28th, Hbm Healthcare Investments (Ca sold 15,939 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.02, for a total value of $175,647.78.
  • On Friday, April 21st, Hbm Healthcare Investments (Ca sold 2,622 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.04, for a total value of $28,946.88.
  • On Thursday, April 20th, Hbm Healthcare Investments (Ca sold 23,932 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.11, for a total value of $265,884.52.
  • On Thursday, April 13th, Hbm Healthcare Investments (Ca sold 32,831 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.24, for a total value of $369,020.44.
  • On Monday, April 10th, Hbm Healthcare Investments (Ca sold 90,594 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.96, for a total value of $992,910.24.

Shares of Nabriva Therapeutics AG (NASDAQ NBRV) traded down 2.05% on Friday, reaching $10.52. The company’s stock had a trading volume of 42,073 shares. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75. The stock has a 50-day moving average price of $9.87 and a 200-day moving average price of $9.52. The company’s market capitalization is $282.11 million.

TRADEMARK VIOLATION NOTICE: “Insider Selling: Nabriva Therapeutics AG (NASDAQ:NBRV) Major Shareholder Sells 1,775 Shares of Stock” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.thecerbatgem.com/2017/07/16/nabriva-therapeutics-ag-nasdaqnbrv-major-shareholder-hbm-healthcare-investments-ca-sells-1775-shares-updated.html.

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Nationwide Fund Advisors bought a new position in shares of Nabriva Therapeutics AG during the first quarter valued at $2,074,000. Almanack Investment Partners LLC. bought a new position in shares of Nabriva Therapeutics AG during the first quarter valued at $1,870,000. Finally, Renaissance Technologies LLC bought a new position in shares of Nabriva Therapeutics AG during the fourth quarter valued at $103,000. Institutional investors own 56.73% of the company’s stock.

A number of research firms recently commented on NBRV. Cantor Fitzgerald began coverage on Nabriva Therapeutics AG in a report on Thursday, June 22nd. They set a “buy” rating and a $16.00 target price for the company. Zacks Investment Research raised Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 target price for the company in a report on Saturday, May 27th. HC Wainwright reaffirmed a “buy” rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Friday, June 30th. ValuEngine raised Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a report on Saturday, June 24th. Finally, Wedbush reaffirmed an “outperform” rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Nabriva Therapeutics AG presently has an average rating of “Buy” and a consensus target price of $15.29.

About Nabriva Therapeutics AG

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.